Executive Summary
ResMed Inc (0KW4.L) reported a robust performance for Q1 2025, achieving a revenue of $1.22 billion, marking a year-over-year increase of 27.15%. This quarterly performance reflects the companyΓ’β¬β’s continued focus on its core sectors Γ’β¬β Sleep and Respiratory Care and Software as a Service, adapting to evolving healthcare needs. Management has emphasized strategic investments into innovation as well as expanding their global footprint, majorly contributing to this success.
The net income surged to $311 million, a 41.90% increase compared to the previous year, underscoring effective operational efficiency and enhanced profitability. ManagementΓ’β¬β’s guidance suggests a positive outlook for the upcoming quarters, bolstered by new product releases and market expansions, which investors should watch closely.
Key Performance Indicators
Revenue
1.22B
QoQ: 0.11% | YoY:27.15%
Gross Profit
717.22M
58.57% margin
QoQ: 1.84% | YoY:19.52%
Operating Income
387.31M
QoQ: 1.60% | YoY:34.02%
Net Income
311.36M
QoQ: 6.54% | YoY:41.90%
EPS
2.12
QoQ: 6.53% | YoY:42.28%
Revenue Trend
Margin Analysis
Key Insights
- **Revenue**: $1.22 billion, up 27.15% YoY and 0.11% QoQ
- **Gross Profit**: $717.22 million, Gross Margin: 58.57% (YoY: +19.52%, QoQ: +1.84%)
- **Operating Income**: $387.31 million, Operating Margin: 31.63% (YoY: +34.02%, QoQ: +1.60%)
- **Net Income**: $311.36 million, Net Margin: 25.43% (YoY: +41.90%, QoQ: +6.54%)
- **EPS**: $2.12, an increase of 42.28% YoY and 6.53% QoQ.